Abstract
Bronchogenic carcinoma is a disease with an unfavorable prognosis, which in a large number of cases is already advanced, often metastatic, at the time of diagnosis. In non-small cell lung cancer (NSCLC), a better understanding of the molecular biology of tumors leads to improved treatment outcomes through targeted treatment based on genetic changes in the tumor that predict the effectiveness of this therapy.
Another treatment modality is immunotherapy, which has confirmed its effectiveness in combination with chemotherapy. Chemotherapy alone is no longer the standard of care for first-line advanced NSCLC.